Unable to load price data. Sorry.


IsoRay, Inc. (NYSE MKT:ISR)

CAPS Rating: 1 out of 5

The Company develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

30 Outperform
11 Underperform

All-Star Players

4 Outperform
6 Underperform

Wall Street

0 Outperform
0 Underperform

Top NYSE MKT:ISR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Lijn44 (< 20)
Submitted March 20, 2014

IsoRay is the exclusive manufacturer of Cesium-131. Cesium-131 allows for the precise treatment of many different cancers.IsoRay's Cesium 131 cancer therapy is FDA approved.IsoRay is dramatically undervalued

TSIF (99.97)
Submitted June 24, 2014

This is my fourth time on this one after the spikes, averaging 15 points on each of the other three calls. Maybe it will bite me eventually, but as I've noted before, these ONE case, recycled Cesium news releases aren't an indication of revenue. They… More


Fools bullish on NYSE MKT:ISR are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about ISR.


Member Avatar Alacrity (< 20) Submitted: 9/2/2015 1:31:13 PM : Outperform Start Price: $1.46 NYSE MKT:ISR Score: -113.28

ISR a small medical device company, is already FDA approved and holds the paten, on Cesium-131 brachytherapy. ISR potentially cures cancer with outstanding results. MD Anderson, named the best cancer hospital, in America is now using the cesium-131. MD Anderson will have the results on, November 7, 2015 . ISR earnings are on Sept 14, 2015, last quarter ISR beat the consensus. In May, CEO Dwight Babcock, commented on the small cell lung cancer result, the stock soared. A very negative press release was released by, Adam Feuerstein resulting in several law suits, the stock then plummeted. Given the outstanding results, of cesium 131 and the ability to cure cancer is a very positive indication this will soon be a winner. Thomson Reuters, just gave the stock a four star out of ten and expected price target of 25.00. I am long in ISR, and I am waiting for some very positive results.


Member Avatar JacksonFool805 (< 20) Submitted: 5/13/2014 5:08:55 PM : Outperform Start Price: $2.35 NYSE MKT:ISR Score: -128.70

They have a propriety cancer fighting treatment already FDA approved with a track record of over 80% effectiveness in patients. Up over 400% ytd and will continue to grow baby grow....


Member Avatar jpat34721 (21.24) Submitted: 5/6/2014 2:32:35 PM : Outperform Start Price: $2.56 NYSE MKT:ISR Score: -132.57

proprietary standard of care cancer therapy with proven results and expanding application.


Find the members with the highest scoring picks in ISR.

Score Leader


IdahoInvestor (34.44) Score: +192.30

The Score Leader is the player with the highest score across all their picks in ISR.

Member Name Member
Call Time
Score Commentary
BTE78 23.95 5/12/2014 Underperform 1Y $2.57 -81.68% +48.91% +130.59 0 Comment
Slade366 94.88 5/23/2014 Underperform 5Y $2.26 -79.20% +48.17% +127.38 0 Comment
ahknaten 94.20 10/15/2014 Underperform 5Y $1.28 -63.28% +51.96% +115.25 0 Comment
PutinDragon 70.46 3/27/2015 Underperform NS $1.59 -70.44% +37.58% +108.02 0 Comment
IdahoInvestor 34.44 3/6/2013 Underperform 5Y $0.54 -12.96% +82.26% +95.22 0 Comment
TinyCapsWatch 99.89 6/6/2016 Underperform 5Y $0.80 -41.51% +33.67% +75.18 0 Comment
Doppelganger 30.63 7/13/2016 Underperform 5Y $0.83 -43.48% +31.19% +74.68 0 Comment
Zencyclone 30.77 10/19/2016 Underperform 5Y $0.69 -31.87% +31.80% +63.67 0 Comment
warrenout2 97.56 11/15/2016 Underperform 5Y $0.59 -20.35% +30.03% +50.38 0 Comment
HoustonThomas 99.73 12/16/2016 Underperform 5Y $0.58 -18.97% +25.23% +44.19 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ISR.